Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Complete Health Nourianz Prior Auth | Open…
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PMN.217

    Clinical Policy: Istradefylline (Nourianz)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.217 alerts

    Get alerted when Policy AZ.CP.PMN.217 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization coverage for Nourianz (istradefylline) for Arizona Medicaid members, including AzCH-CCP and Care1st. It establishes initial and continued-therapy criteria for adults with Parkinson's disease experiencing off episodes while receiving levodopa/carbidopa.

    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Istradefylline (Nourianz)
    Policy CodePolicy AZ.CP.PMN.217
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateFeb 1, 2020
    Last ReviewJan 18, 2021
    Next Review DateNot specified
    Key ActionSubmit documentation supporting that the member meets all applicable approval criteria for Nourianz.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was revised to specify that the criteria also apply to Care1st.

    The policy history reports that the 1Q 2021 annual review found no significant changes and updated references.

    The policy history reports addition of Care1st branding and wording specifying that the criteria also apply to Care1st.

    40 mg/dayMaximum Nourianz dose
    6 monthsInitial approval duration
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Continued-therapy approval duration
    2Adjunctive drugs to try
    Off-label policyUnauthorized indications

    General Coverage Criteria

    Initial therapy - Parkinson's disease

    Covered when ALL of the following are met:

    Initial approval criteria

    • Diagnosis and age: Member has a diagnosis of Parkinson's disease and is at least 18 years of age.Age >= 18 years
    • Off time: Member is experiencing off time while receiving levodopa/carbidopa therapy.
    • Adjunctive treatment failure

      • COMT inhibitor: Entacapone or tolcapone.
      • Dopamine agonist: Ropinirole, ropinirole ER, pramipexole, pramipexole ER, or rotigotine (Neupro).
    • Combination therapy: Nourianz is prescribed in combination with levodopa/carbidopa.
    • Dose limit: The dose does not exceed 40 mg (1 tablet) per day.<= 40 mg/day

    Continuation therapy - Parkinson's disease

    Covered when ALL of the following are met:

    Continuation criteria

    • Existing coverage or prior approval: Member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
    • Positive response: Member is responding positively to therapy.
    • Dose increase limit: If the request is for a dose increase, the new dose does not exceed 40 mg (1 tablet) per day.<= 40 mg/day

    Continuation therapy - Other diagnoses/indications

    Covered when either criterion 1 or criterion 2 is met:

    Other diagnoses or indications

    • Criterion 1: Existing coverage with positive response: Member is currently receiving the medication through the Centene benefit, and documentation supports a positive response to therapy.
    • Criterion 2: Off-label policy referral: If the diagnosis is not specifically listed under the policy's unauthorized indications, refer to the applicable off-label use policy AZ.CP.PMN.53 for Arizona Medicaid.

    Non-FDA-approved indications

    Not covered unless the applicable off-label policy supports the indication:

    Unauthorized indications: Non-FDA-approved indications not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy AZ.CP.PMN.53 for Arizona Medicaid.

    Non-FDA-approved indications that are not addressed in this policy are not covered unless sufficient documentation of efficacy and safety supports the indication under the applicable Arizona Medicaid off-label use policy, AZ.CP.PMN.53.

    Initial Therapy for Parkinson's Disease

    Initial therapy for Parkinson's disease

    Covered when ALL of the following are met:

    Initial approval - Parkinson's disease

    • Diagnosis and age: Member has a diagnosis of Parkinson's disease and is at least 18 years of age.Age >= 18 years
    • Off time on levodopa/carbidopa: Member is experiencing off time while receiving levodopa/carbidopa therapy.
    • Adjunctive treatment failure

      • COMT inhibitor: Entacapone or tolcapone.

    Continuation Therapy

    Continued therapy for Parkinson's disease

    Covered when ALL of the following are met:

    Continued therapy - Parkinson's disease

    • Existing coverage or prior approval: Member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
    • Positive response: Member is responding positively to therapy.
    • Dose increase limit: If the request is for a dose increase, the new dose does not exceed 40 mg (1 tablet) per day.<= 40 mg/day

    Required Adjunctive Therapy Trials

    StepRequirementClassListed options
    1Try two adjunct drugs in combination with levodopa/carbidopa; each must be from a different class. The requirement may be waived if the drug is contraindicated or causes clinically significant adverse effects.COMT inhibitorEntacapone (Comtan/Stalevo) or tolcapone
    1Try two adjunct drugs in combination with levodopa/carbidopa; each must be from a different class. The requirement may be waived if the drug is contraindicated or causes clinically significant adverse effects.Dopamine agonistRopinirole, ropinirole ER, pramipexole, pramipexole ER, or Neupro (rotigotine)

    Nourianz Quantity Limit

    Quantity Limit
    MedicationIstradefylline (Nourianz)
    Maximum quantity40 mg
    Applicable dosing periodPer day; equivalent to 1 tablet

    Dose and Administration Limits

    Maximum Nourianz Dose
    Maximum dose40 mg per day
    Tablet limit1 tablet per day
    UseAdjunctive treatment with levodopa/carbidopa in adults with Parkinson's disease experiencing off episodes

    Prior Authorization and Documentation

    Prior Authorization

    Submit Prior-Authorization Documentation

    Submit prior-authorization documentation demonstrating that the member meets all applicable Nourianz approval criteria for the requested use. For initial therapy, document Parkinson’s disease, age 18 years or older, experiencing “off” time on levodopa/carbidopa, concurrent levodopa/carbidopa therapy, and a dose not exceeding 40 mg (1 tablet) daily.

    • Covered diagnosis: Parkinson’s disease.
    • Member is age ≥ 18 years.
    • Member experiences “off” time while receiving levodopa/carbidopa therapy.
    • Nourianz is prescribed in combination with levodopa/carbidopa.
    • Requested dose does not exceed 40 mg (1 tablet) per day.
    Step Therapy

    Document Failure of Two Adjunctive Agents

    Document failure of two adjunctive drugs used in combination with levodopa/carbidopa, with each agent selected from a different drug class, unless contraindicated or clinically significant adverse effects occurred.

    Medication and Indication Background

    Istradefylline (Nourianz) is an adenosine A2A receptor antagonist. It is FDA-indicated as adjunctive treatment with levodopa/carbidopa in adults with Parkinson's disease who experience off episodes—the return of symptoms such as bradykinesia, resting tremor, or rigidity when the levodopa effect wears off. In clinical use, Nourianz is added to levodopa/carbidopa to address these motor fluctuations.

    Clinical Terms and Abbreviations

    Definitions
    AbbreviationCOMT
    Full termCatechol-O-methyl transferase
    Policy contextCOMT inhibitors are one of the adjunctive drug classes addressed in initial approval criteria
    Definitions
    AbbreviationMAO-B
    Full termMonoamine oxidase type B
    ReferenceListed in the policy's abbreviation and acronym key
    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Istradefylline (Nourianz)
    Policy CodePolicy AZ.CP.PMN.217
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateFeb 1, 2020
    Last ReviewJan 18, 2021
    Next Review DateNot specified
    Key ActionSubmit documentation supporting that the member meets all applicable approval criteria for Nourianz.
    SourceLink
    On This Page
    General Coverage CriteriaInitial Therapy for Parkinson's DiseaseContinuation TherapyRequired Adjunctive Therapy TrialsNourianz Quantity LimitDose and Administration LimitsPrior Authorization and DocumentationMedication and Indication BackgroundClinical Terms and Abbreviations
  1. Dopamine agonist: Ropinirole, ropinirole ER, pramipexole, pramipexole ER, or rotigotine (Neupro).
  2. Combination therapy: Nourianz is prescribed in combination with levodopa/carbidopa.
  3. Dose limit: The dose does not exceed 40 mg (1 tablet) per day.<= 40 mg/day
  4. Continued therapy for other diagnoses/indications

    Covered when either criterion 1 or criterion 2 is met:

    Continued therapy for other diagnoses or indications

    • Criterion 1: Existing coverage with positive response: Member is currently receiving the medication through the Centene benefit, and documentation supports a positive response to therapy.
    • Criterion 2: Off-label policy referral: If the diagnosis is not specifically listed under the policy's unauthorized indications, refer to the applicable off-label use policy AZ.CP.PMN.53 for Arizona Medicaid.
    • COMT inhibitor: entacapone (Comtan/Stalevo; AHCCCS preferred) or tolcapone.
    • Dopamine agonist: ropinirole or ropinirole ER (AHCCCS preferred), pramipexole or pramipexole ER (AHCCCS preferred), or Neupro (rotigotine).
    • Prior authorization may be required for the adjunctive agents.
    Documentation Required

    Provide Supporting Clinical Documentation

    Include supporting clinical documentation for the request, such as office chart notes, laboratory results, or other relevant clinical information demonstrating that the member meets the applicable approval criteria.

    • Office chart notes.
    • Laboratory results.
    • Other clinical information supporting medical necessity and fulfillment of approval criteria.
    Documentation Required

    Document Positive Response for Continued Therapy

    For continued therapy under other diagnoses or indications, document that the member is currently receiving Nourianz through the Centene benefit and has had a positive response to treatment. Approval duration is 12 months.

    • Document current receipt of the medication through the Centene benefit.
    • Document positive response to therapy.
    • Approval duration: 12 months.
    Denial Risk

    Failure to Meet Coverage Criteria May Result in Denial

    Coverage may be denied when required diagnosis, age, “off” time, adjunctive-therapy history, combination therapy, dose, or other applicable criteria are not documented or are not met. Non-FDA-approved indications not addressed by the policy are not authorized unless supported under the applicable off-label use policy.

    • Risk of denial if the member does not have Parkinson’s disease, is younger than 18 years, or is not experiencing “off” time on levodopa/carbidopa.
    • Risk of denial if failure of two adjunctive agents from different classes is not demonstrated, absent contraindication or clinically significant adverse effects.
    • Risk of denial if Nourianz is not prescribed with levodopa/carbidopa or the dose exceeds 40 mg daily.
    • For diagnoses or indications not specifically listed, refer to the applicable off-label use policy, AZ.CP.PMN.53 for Arizona Medicaid.
    • Non-FDA-approved indications not addressed in the policy are not authorized unless sufficient efficacy and safety documentation meets the applicable off-label use policy.
    Definitions
    AbbreviationPD
    Full termParkinson's disease
    Policy populationAdults with Parkinson's disease experiencing off time while receiving levodopa/carbidopa therapy
    Definitions
    DefinitionA return of Parkinson's disease symptoms when the L-dopa treatment effect wears off after each dosing interval
    SymptomsMay include bradykinesia, resting tremor, or rigidity
    Treatment contextOccurs when the levodopa effect wears off
    Definitions
    DefinitionThe alternation between on time and off time
    On timeThe period when Parkinson's disease symptoms are successfully suppressed by L-dopa
    Off timeThe period when Parkinson's disease symptoms return